Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 2/20 | 0.41 |
| ▸ | PGK2 | P07205 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3231825 | 0.76 | PGK1 (0.42) | PGK1PGK2SMN1; SMN2ACP3 | |
| SCHEMBL10279722 | 0.75 | NPY5R (0.35) | — | |
| SCHEMBL3509336 | 0.74 | — | — | |
| SCHEMBL939997 | 0.73 | PGK1 (0.46) | PGK1PGK2SMN1; SMN2 | |
| SCHEMBL27549996 | 0.72 | RECQL (0.33) | — | |
| SCHEMBL21067202 | 0.71 | — | — | |
| SCHEMBL27167090 | 0.70 | HTT (0.43) | — | |
| SCHEMBL3511769 | 0.70 | — | — | |
| SCHEMBL30363964 | 0.70 | — | — | |
| SCHEMBL398115 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| EP-2638022-B1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL MYERS SQUIBB CO (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2638022-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | Bristol-Myers Squibb Company (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| WO-2012064603-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | GRM5, GRIK5, GRM1 | PGK1 1141/4885PGK2 1007/4885SMN1; SMN2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.